Inhalation Sciences: Senior KOLs and research experts join new ISAB Scientific Advisory Board

(Stockholm, Sweden, May 19, 2021) Prominent experts and KOLs from universities across Europe have joined Inhalation Sciences’ new Scientific Advisory Board. The Board will meet first on June 1, 2021.

ISAB submitted its CTA (Clinical Trial Application) for a clinical study on PreciseInhale^® in humans, to the Swedish Medical Product Agency (Läkemedelsverket) at the end of March 2021. The first healthy volunteers are expected to enter the clinical trial in June and the study is planned to be finalized before the end of 2021.

ISAB’s new Scientific Advisory Board will provide input on how to engage the inhalation research world once PreciseInhale^® will be available for studies on humans. The new Board includes prominent members of the pharmaceutical academic and industrial world including Carsten Ehrhardt, Professor in Pharmaceutics at Trinity College in Dublin (Ireland), Per Wollmer, Professor of Clinical Physiology at Lund University (Sweden), Martin Wehling at the Department of Clinical Pharmacology, University of Heidelberg (Germany) and Gary Pitcairn at GRP Consulting, Gothenburg (Sweden).

Clinical validation of PreciseInhale^® would be a historic development not just for ISAB, but potentially for inhalation research as a whole. PreciseInhale^® would be the first aerosol generation platform that could be used from the drug discovery phase, through preclinical in vitro and in vivo studies all the way to phase I clinical trials in humans.

ISAB CEO Manoush Masarrat: “At Inhalation Sciences, it is paramount for us to be at the forefront of the inhalation research world. Our aim with the engagement of our new Scientific Advisory Board is to transform their expertise and valuable input into more targeted new product development, hence accelerating the innovation rate.”

For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153